Avenanthramides, polyphenols from oats, exhibit anti-inflammatory and anti-itch activity

  • Runa Sur
  • Anu Nigam
  • Devon Grote
  • Frank Liebel
  • Michael D. Southall
Original Paper

DOI: 10.1007/s00403-008-0858-x

Cite this article as:
Sur, R., Nigam, A., Grote, D. et al. Arch Dermatol Res (2008) 300: 569. doi:10.1007/s00403-008-0858-x

Abstract

Oatmeal has been used for centuries as a soothing agent to relieve itch and irritation associated with various xerotic dermatoses; however few studies have sought to identify the active phytochemical(s) in oat that mediate this anti-inflammatory activity. Avenanthramides are phenolic compounds present in oats at approximately 300 parts per million (ppm) and have been reported to exhibit anti-oxidant activity in various cell-types. In the current study we investigated whether these compounds exert anti-inflammatory activity in the skin. We found that avenanthramides at concentrations as low as 1 parts per billion inhibited the degradation of inhibitor of nuclear factor kappa B-α (IκB-α) in keratinocytes which correlated with decreased phosphorylation of p65 subunit of nuclear factor kappa B (NF-κB). Furthermore, cells treated with avenanthramides showed a significant inhibition of tumor necrosis factor-α (TNF-α) induced NF-κB luciferase activity and subsequent reduction of interleukin-8 (IL-8) release. Additionally, topical application of 1–3 ppm avenanthramides mitigated inflammation in murine models of contact hypersensitivity and neurogenic inflammation and reduced pruritogen-induced scratching in a murine itch model. Taken together these results demonstrate that avenanthramides are potent anti-inflammatory agents that appear to mediate the anti-irritant effects of oats.

Keywords

Inflammation Itch Avenanthramide Cytokine NF-κB Keratinocyte 

Abbreviations

RTX

Resiniferatoxin

TNFα

Tumor necrosis factor-α

IL-8

Interleukin-8

NF-κB

Nuclear factor kappa beta

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • Runa Sur
    • 1
  • Anu Nigam
    • 1
  • Devon Grote
    • 1
  • Frank Liebel
    • 1
  • Michael D. Southall
    • 1
  1. 1.Preclinical PharmacologySkin Research Center, Johnson & Johnson Consumer ProductsSkillmanUSA

Personalised recommendations